Avalo Therapeutics (AVTX) Total Debt (2014 - 2025)

Avalo Therapeutics has reported Total Debt for 11 years, with the latest figure at $370000.0 in Q2 2025.

• For the quarter ending Q2 2025, Total Debt changed N/A year-over-year to $370000.0; the trailing twelve-month figure through Jun 2025 stood at $370000.0 (changed N/A YoY), and the FY2024 full-year result was $360000.0, changed N/A from the prior year.
• Total Debt for Q2 2025 stood at $370000.0, up from $360000.0 in the prior quarter.
• The five-year high for Total Debt was $32.8 million in Q4 2021, with the low at $360000.0 in Q4 2024.
• Historically, Total Debt has averaged $11.6 million across 5 years, with a median of $12.0 million in 2022.
• The largest YoY upside for Total Debt was 58.93% in 2022 against a maximum downside of 58.93% in 2022.
• Avalo Therapeutics' Total Debt stood at $32.8 million in 2021, then sank by 58.93% to $13.5 million in 2022, then decreased by 22.36% to $10.5 million in 2023, then tumbled by 96.56% to $360000.0 in 2024, then increased by 2.78% to $370000.0 in 2025.
• The last three Total Debt figures came in at $370000.0 (Q2 2025), $360000.0 (Q1 2025), and $360000.0 (Q4 2024), per Business Quant data.